Table 3 NIV-failed vs NIV-successful groups: laboratory findings and therapies statistical analysis

Glicemia (mg/dL)

139.0 [117.0–177.0]

160.5 [129.5–202.5]

123.5 [112.0–154.0]

0.0039

Azotemia (mg/dL)

60.5 [46.2–71.0]

63.5 [49.5–96.0]

60.0 [45.0–69.0]

0.2284

Creatinine (mg/dL)

0.74 [0.61–0.96]

0.73 [0.56–1.09]

0.74 [0.66–0.91]

0.7802

eGFR (mL/min)

95.5 [73.3–106.7]

91.5 [66.7–99.3]

100.8 [88.8–113.3]

0.0104

Total protein (g/dL)

6.0 ± 0.6

6.1 ± 0.6

6.1 ± 0.6

0.7854

Albumin (g/dL)

0.7 [0.6–0.9]

2.9 ± 0.3

3.1 ± 0.4

0.0051

Bilirubin (mg/dL)

3.0 ± 0.4

0.8 [0.6–0.9]

0.7 [0.5–0.9]

0.4540

Ammonium (μg/dL)

84.0 [65.0–113.0]

84.0 [63.0–110.7]

85.5 [67.5–115.5]

0.9250

Sodium (mEq/L)

138.0 [136.0–140.0]

138.0 [136.0–143.0]

138.0 [136.0–140.0]

0.3287

Potassium (mEq/L)

4.4 ± 0.5

4.2 ± 0.4

4.6 ± 0.5

0.0013

Clorum (mEq/L)

102.0 [99.5–104.0]

103.0 [100.2–105.7]

102.0 [99.0–103.0]

0.1595

Calcium (mg/dL)

8.5 [8.1–8.8]

8.4 [8.1–8.6]

8.6 [8.3–8.9]

0.0443

Magnesium (mg/dL)

2.2 ± 0.3

2.3 [2.0–2.5]

2.2 [2.0–2.4]

0.8127

AST (U/L)

31.5 [25.0–48.2]

29.0 [23.0–45.5]

34.0 [27.0–50.0]

0.3218

ALT (U/L)

37.0 [26.0–56.0]

30.0 [20.0–42.5]

49.5 [28.0–79.0]

0.0016

LDH (U/L)

413.0 [319.5–598.0]

456.5 [348.0–614.5]

387.5 [299.0–550.0]

0.1344

CPK (U/L)

69.5 [40.5–141.5]

61.5 [45.0–132.0]

82.0 [34.0–156.0]

0.7168

Troponin (ng/L)

11.3 [5.0–21.3]

13.5 [8.4–38.6]

6.0 [3.7–13.9]

0.0008

Mioglobin (ng/mL)

62.3 [37.8–110.9]

75.5 [39.2–169.5]

49.9 [32.5–91.5]

0.0894

CK-MB (ng/mL)

1.7 [1.1–2.8]

2.1 [1.3–3.9]

1.3 [0.9–1.9]

0.0038

BNP (pg/mL)

53.0 [33.0–123.2]

86.0 [46.5–196.2]

34.0 [21.0–58.0]

0.0001

Hb (g/dL)

13.7 [12.2–14.6]

13.1 [12.1–13.9]

14.3 [12.4–14.9]

0.0327

WBC (× 10³)

11.0 [8.1–13.3]

11.8 [9.1–13.3]

10.1 [7.6–13.3]

0.1017

Neutrophil (× 10³)

9.6 [7.0–11.7]

10.3 [8.0–12.0]

8.4 [6.9–10.9]

0.0542

Lymphocytes

727 [536–999]

758 ± 330

850 ± 348

0.2255

Eosinophil

85 [48–154]

96 [53–156]

78 [39–149]

0.2906

Monocyte

437 [318–627]

433 [317–580]

476 [322–700]

0.5121

Basophil

13 [8–24]

13 [10–24]

12 [5–21]

0.2182

Neutrophil/lymphocyte ratio

12.1 [8.8–18.0]

15.1 [10.4–19.7]

10.3 [7.4–14.4]

0.0080

Platelet (× 10³)

266.6 ± 103.9

247.4 ± 104.6

288.8 ± 99.9

0.0714

aPTT (sec)

29.9 [26.8–32.8]

31.2 [29.3–34.0]

27.9 [25.9–30.6]

0.0041

INR

1.13 [1.04–1.23]

1.19 [1.04–1.31]

1.12 [1.04–1.18]

0.0921

Firbinogen (mg/dL)

538.5 [471.0–670.0]

505.5 [424.5–588.0]

596.0 [512.0–699.0]

0.0166

D-dimer (ng/mL)

1060.0 [680.7–2495.0]

1460.0 [860.0–3825.0]

820.0 [530.0–1260.0]

0.0037

AT III (%)

86.3 ± 15.9

82.4 ± 16.2

90.8 ± 14.4

0.0161

CRP (mg/dL)

7.3 [3.6–12.7]

8.9 [5.1–14.2]

6.1 [3.6–9.4]

0.0762

PCT (ng/mL)

0.10 [0.06–0.23]

0.13 [0.09–0.35]

0.08 [0.05–0.14]

0.0141

SOFA score

3 [3–4]

4 [3–5]

3 [3–4]

0.0808

Tocilizumab (%)

16 (19.5%)

6 (13.6%)

10 (26.3%)

0.1490

Eculizumab (%)

2 (2.4%)

1 (2.3%)

1 (2.6%)

0.9163

Remdesivir (%)

6 (7.3%)

2 (4.5%)

4 (10.5%)

0.2997